Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats

Autor:	Eva Zschiesche, Rainer K. A. Roepke, Thierry Pobel, Wolfgang Loehlein, Nadja Rohdich, Maria José Gil, Oliver Wolf
Rok vydání:	2018
Předmět:	0301 basic medicine Veterinary medicine Fluralaner Flea Insecticides Administration Topical Cat Diseases chemistry.chemical_compound Random Allocation 0302 clinical medicine Ticks Germany Single-Blind Method Fipronil CATS biology 030108 mycology & parasitology Moxidectin Rhipicephalus Infectious Diseases Treatment Outcome Fleas Macrolides Rhipicephalus sanguineus 030231 tropical medicine Tick lcsh:Infectious and parasitic diseases Feline Isoxazoline 03 medical and health sciences Flea Infestations parasitic diseases Animals lcsh:RC109-216 Ixodes Research Ownership Isoxazoles biology.organism_classification bacterial infections and mycoses Bravecto Plus Tick Infestations chemistry Spain Cats Pyrazoles Parasitology Ectoparasites
Zdroj:	Parasites & Vectors Parasites & Vectors, Vol 11, Iss 1, Pp 1-11 (2018)
ISSN:	1756-3305
Popis:	Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain. Methods Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment. Results In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated. Conclusions A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c15b6dc408b37fd900c4cc56518237a7 https://pubmed.ncbi.nlm.nih.gov/30454052 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.